Kyle Gano Sells 1,541 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Kyle Gano sold 1,541 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $152.87, for a total value of $235,572.67. Following the completion of the sale, the chief executive officer now owns 136,778 shares of the company’s stock, valued at $20,909,252.86. This trade represents a 1.11 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kyle Gano also recently made the following trade(s):

• On Wednesday, January 15th, Kyle Gano sold 65,000 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $141.50, for a total transaction of $9,197,500.00.

Neurocrine Biosciences Stock Performance

NBIX stock opened at $150.51 on Friday. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The firm has a market cap of $15.24 billion, a PE ratio of 40.35 and a beta of 0.33. The firm’s 50 day moving average price is $138.41 and its 200-day moving average price is $131.64.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Thursday, February 6th. The company reported $1.00 EPS for the quarter, missing analysts’ consensus estimates of $1.62 by ($0.62). Neurocrine Biosciences had a net margin of 17.21% and a return on equity of 15.68%. Equities research analysts predict that Neurocrine Biosciences, Inc. will post 3.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on NBIX shares. Morgan Stanley increased their price objective on shares of Neurocrine Biosciences from $170.00 to $185.00 and gave the company an “overweight” rating in a report on Tuesday. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Raymond James reiterated an “outperform” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research note on Thursday, October 10th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research report on Friday, December 20th. Finally, Piper Sandler reiterated an “overweight” rating and set a $160.00 price target on shares of Neurocrine Biosciences in a research report on Monday, December 23rd. Five analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $166.85.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Cetera Investment Advisers lifted its holdings in shares of Neurocrine Biosciences by 7.9% in the 2nd quarter. Cetera Investment Advisers now owns 7,112 shares of the company’s stock worth $979,000 after acquiring an additional 519 shares during the last quarter. Sanctuary Advisors LLC purchased a new stake in Neurocrine Biosciences in the second quarter valued at approximately $510,000. Handelsbanken Fonder AB lifted its stake in Neurocrine Biosciences by 20.7% during the third quarter. Handelsbanken Fonder AB now owns 26,867 shares of the company’s stock worth $3,096,000 after purchasing an additional 4,600 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of Neurocrine Biosciences by 11.9% during the third quarter. GAMMA Investing LLC now owns 1,738 shares of the company’s stock worth $200,000 after buying an additional 185 shares during the period. Finally, CWM LLC grew its stake in shares of Neurocrine Biosciences by 15.1% in the third quarter. CWM LLC now owns 7,884 shares of the company’s stock valued at $908,000 after buying an additional 1,035 shares in the last quarter. Hedge funds and other institutional investors own 92.59% of the company’s stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.